Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Kennedy professor is one of eight researchers from Oxford University who received a prestigious fellowship from the Royal Society in recognition of their work in the fields of science and medicine.

Horizontal portrait of Professor Michael Dustin

The Royal Society Fellowship has been awarded to Professor Michael Dustin for his contribution to immunology research. His work has established the concept of the immunological synapse that describes how T lymphocytes recognise and respond to target cells. He pioneered the use of fluorescently tagged native molecules from antigen-presenting cells in supported planar bilayers to determine the molecules and pathways that contribute to T cell activation following antigen-recognition. He is also recognised as one of the first to develop imaging approaches to visualise the dynamics of the immune response in tissues. His work has been fundamental to the development of therapies that target the T cell response including in the field of vaccines and immune-oncology.

Commenting on the recognition Professor Dustin said: ‘It is a profound honour to become a fellow of the Royal Society.  This is a remarkable privilege and opportunity that I never expected and deeply appreciate. I look forward to doing all I can to help the Royal Society deliver on its priorities.’

Professor Dame Fiona Powrie, Director of the Kennedy Institute said: ‘Mike’s well-deserved recognition by the Royal Society reflects his pioneering research which has taught us so much about T cell activation informing immune therapy approaches for cancer and autoimmune diseases.'